depression

By Laura Lovett 12:04 pm December 5, 2019
When it comes to mental health apps, validation is a hot topic. But studying those apps can pose some hefty challenges. A recent meta analysis published online in the Journal of Affective Disorders found that studies of apps for depressive symptoms had around a 50% dropout rate when accounting for bias.  However, researchers discovered that the rate was lower when the apps included a human...

Credit: Flow

By Leontina Postelnicu 02:24 am October 31, 2019
Flow Neuroscience is working with outpatient clinics in London’s Harley Street district in a partnership that will see its brain stimulation headset be offered to patients as an add-on treatment for depression. The Swedish startup announced this morning that around 10 centres, including the Chelsea Psychology Clinic, would start offering the device in combination with traditional therapy and...
By Dave Muoio 02:36 pm October 10, 2019
Facebook is looking serve as the facilitator of constructive, supportive mental health discussions between friends with today’s release of new features for the social media network and its private messaging service, Messenger. Timed for release on the World Health Organization’s World Mental Health Day, the company has unveiled a “Let’s Talk” photo filter for Stories that invites peers struggling...
By Laura Lovett 02:53 pm September 30, 2019
With the staggering shortage of mental health practitioners worldwide, more and more startups are looking for alternative ways to provide patient care. One of the most popular technologies is chatbots. Now we are seeing one more entrance emerge into that market. On Thursday, Sweden- and UK-based medical device company Flow, best known for its brain stimulation headset, launched a new chatbot...
By Laura Lovett 02:53 pm July 24, 2019
This morning neurology-focused health startup Flow announced that it landed a $1.5 million investment. This latest round was led by Khosla Ventures.  WHAT THEY DO The Swedish startup is focused on treating and supporting users with depression. Flow is a two-part system including a brain stimulation headset and a therapy app. When the user puts on the device, it delivers electrical signals to...

Credit: Flow

By Leontina Postelnicu 07:49 am July 24, 2019
Malmö-based medical device startup Flow has landed $1.5m (approximately €1.35m) in funding in a round led by Khosla Ventures, it was announced this week. The new funds will be used to support the European rollout of Flow's brain stimulation headset and therapy app, developed to treat depression, which were launched in the UK and Sweden earlier this year. “The Khosla Ventures investment will...

Credit: Flow

By Leontina Postelnicu 12:53 pm June 4, 2019
This morning, Malmö-based medical device company Flow has announced that it is launching its brain stimulation headset and therapy app to treat depression in the UK. HOW IT WORKS Priced at £399, the headset uses transcranial direct current stimulation (tDCS) - a non-invasive treatment using direct electronic currents to stimulate specific parts of the brain in order to help rebalance activity,...
By Dave Muoio 03:36 pm May 16, 2019
Help from above. The Department of Justice has taken the side of tech-enabled insurer Oscar Health in a federal antitrust suit it filed in November of last year against Florida Blue, Crain’s New York Business reports. While Oscar’s motion for a temporary injunction was rejected by a federal judge back in February, the DOJ filed a statement in April arguing that Florida Blue had incorrectly...
By Dave Muoio 01:13 pm May 6, 2019
Editor's Note: An original headline for this story contained an error, and has since been corrected. Boston- and San Francisco-based Pear Therapeutics, maker of prescription digital therapeutics for substance abuse, has kicked off a feasibility study for Pear-006, an in-development treatment for depressive symptoms in those with multiple sclerosis (MS). Pear Therapeutics has been developing Pear-...
By Dave Muoio 03:57 pm January 24, 2019
The acceptability, safety, feasibility and preliminary efficacy of Meru Health’s digital therapeutic for depression will be evaluated in a new two-year investigation conducted by Stanford Medicine and VA Palo Alto Health Care System researchers. According to a clinicaltrials.gov listing, the research program will enroll older adults aged at least 40 years with depressive symptoms in two studies...